Corbus Pharmaceuticals's Earnings: A Preview

On Tuesday, November 10, Corbus Pharmaceuticals CRBP will release its latest earnings report. Benzinga's outlook for Corbus Pharmaceuticals is included in the following report.

What Are Earnings, Net Income, And Earnings Per Share?

Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS.

Earnings And Revenue

Corbus Pharmaceuticals EPS loss is expected to be around $0.42, according to sell-side analysts. Sales will likely be near $2.31 million. In the same quarter last year, Corbus Pharmaceuticals reported a loss per share of $0.32 on sales of $2.59 million.

Why Analyst Estimates And Earnings Surprises Are Important

Analysts who cover this company will publish forward-looking estimates of its revenue and EPS each quarter. Averaging together every EPS and revenue prediction that each analyst makes about a company in a quarter yields the "consensus estimates." A company posting earnings or revenue above or below the consensus estimate is known as an "earnings surprise" and may move the stock by a considerable margin.

The analyst consensus estimate would represent a 31.25% decline in the company's EPS figure. Revenue would have fallen 10.81% from the same quarter last year. Here is how the company's reported EPS has stacked up against analyst estimates in the past:

Stock Performance

Shares of Corbus Pharmaceuticals were trading at $1.13 as of November 06. Over the last 52-week period, shares are down 73.39%. Given that these returns are generally negative, long-term shareholders are probably upset going into this earnings release.

Do not be surprised to see the stock move on comments made during its conference call. Corbus Pharmaceuticals is scheduled to hold the call at 08:30:00 ET and can be accessed here.